Therefore, we hypothesise that strategies to enrich CD8_C8_CXCL13 T cells and engineer TCRs from both CD8_C8_CXCL13 and CD8_C11_HAVCR2 T cells could enhance the efficacy of adoptive T cell therapy in cancer treatment. Here, CXCL13 is linked to cancer.